Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604704 · ClinicalTrials.gov registry record · Phase 2
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
A Phase 2 study, sponsored by AgelessRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT04604704: Completed Phase 2 study, sponsored by AgelessRx.
NCT04604704 is a Phase 2 study that has completed, run by AgelessRx. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04604704, a Phase 2 study, has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
Primary Outcome
Reduction of fatigue score from baseline as measured by the Chalder fatigue scale in post-COVID-19 syndrome by treatment with LDN and NAD+. The Chalder scale has a minimum value of 0 and a maximum value of 33, and the higher the score the more severe the fatigue symptoms are.
Interventions
- DRUG Naltrexone
- DIETARY_SUPPLEMENT NAD+
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2023-01-23 |
| Phase | Phase 2 |
What the finished NCT04604704 record still lists
NCT04604704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Naltrexone is the first listed.
NCT04604704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04604704 about?
NCT04604704 is a clinical study titled "Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome". Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
What is the current status of trial NCT04604704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-01-28. Estimated completion is 2023-01-23.
What interventions are being tested in trial NCT04604704?
The interventions under investigation include: Naltrexone (DRUG), NAD+ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04604704?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04604704's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI